Photo: CDC/Debora Cartagena/CDCLegislators, facing an election year, are starting to take action in an attempt to control the drug epidemic surrounding heroin and other opioid abuse.
Stories on how heroin and other opioid abuse shattering communities have been the focus of many powerful pieces in media outlets across the country. After years of inaction, Washington, D.C. ,has begun turning its attention to the issue and moving toward some possible action.
But covering the moving parts of the Department of Health and Human Services, Congress and the White House in tackling the issue is akin to tracking a moving target, all complicated by election-year politicking. What’s a reporter – especially one outside D.C. – to do? Continue reading →
Pia Christensen (@AHCJ_Pia) is the managing editor/online services for AHCJ. She manages the content and development of healthjournalism.org, coordinates AHCJ's social media efforts and edits and manages production of association guides, programs and newsletters.
Carla K. Johnson (@CarlaKJohnson) is a medical writer at The Associated Press and has covered health and medicine since 2001. A former member of AHCJ's board of directors, she leads the Chicago AHCJ chapter.
Photo: Carla K. JohnsonCraig Garthwaite, assistant professor, Northwestern University’s Kellogg School of Management (left); Roy Guharoy, Pharm.D. vice president and chief pharmacy officer for the Resource Group at Ascension (middle); and independent journalist and AHCJ member Duncan Moore (right) spoke at the Chicago chapter event “Drug Pricing: Covering the Controversy” at Columbia College in Chicago on Feb. 23.
A blockbuster hepatitis C drug costs $84,000, straining state budgets. Martin Shkreli acquires the rights to a generic and raises its price 5,000 percent. Presidential candidates react to the public outcry, claiming they know what to do about the drug prices.
What does it all mean? Until recently, “there’s been an equilibrium in the public mind between a free market regimen of the market setting prices and what the public and payers are willing to pay,” said independent journalist Duncan Moore, “but there are indications this informal tradeoff has begun to swing out of control.” Continue reading →
Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.
In an effort to help consumers get a better handle on drug prices, five U.S. senators — all Democrats — are pressuring the Centers for Medicare & Medicaid Services to be more forthcoming about efforts to contain costs and help seniors cope with the high costs of prescription drugs.
Sen. Mark R. Warner (D-Va.), Sen. Bill Nelson (D-Fla.), Sen. Jeanne Shaheen (D-N.H.), Sen. Heidi Heitkamp (D-N.D.), and Sen. Tim Kaine (D-Va.) cosigned a letter on Dec. 17 to CMS Acting Administrator Andrew Slavitt, seeking more information on the agency’s efforts to maximize the agency’s existing authorities on prescription drug costs. Continue reading →
Health insurers are trying a wide variety of methods to link drug costs to the value medications deliver to patients. Value-based payment strategies bear watching for two reasons. First, they are aimed at controlling the high costs of prescription medications, and, second, they could usher in new ways of pricing all medications.
The idea that insurers should link a drug’s value to price is not new, but it is gaining traction, at least among private health plans. One proposal calls for paying for drugs based on the quality-adjusted life year, or QALY, a measure used to quantify the value of treatment. Continue reading →